Volume 17, Number 2—February 2011
CME ACTIVITY - Synopsis
Hepatitis E Virus and Neurologic Disorders
|Patient no.||Relevant medical status||HEV infection phase†||HEV genotype||Serum
|HEV IgG/IgM||HEV RNA||ALT, IU/L†||Bilirubin, µmol/L||HEV RNA||Protein level, g/L||Leukocytes, cells/mm3|
|4||Kidney–pancreas transplant recipient||Chronic||3f||+/+||+||173||19||+||0.71||1|
|5||Kidney transplant recipient||Chronic||3f||–/+||+||110||12||+||0.8||8|
|6||Kidney transplant recipient||Chronic||3f||+/+||+||105||12||+||0.76||7|
*HEV, hepatitis E virus; Ig, immunoglobulin; ALT, alanine aminotransferase; +, positive; –, negative; ND, not done.
†At time of examination for neurologic symptoms.
‡This patient had positive IgG and IgM Wantai assay results throughout but had negative HEV IgG and IgM results for 3 separate Genelabs assays during 2007–2008.
- Page created: July 13, 2011
- Page last updated: July 13, 2011
- Page last reviewed: July 13, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)